• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Purple Biotech Ltd ADR (NQ: PPBT )

    0.3678 UNCHANGED
    Streaming Delayed Price Updated: 3:58 PM EDT, Aug 19, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 0.3678
    Bid (Size) 0.3538 (20)
    Ask (Size) 0.3757 (2)
    Prev. Close 0.3678
    Today's Range 0.3678 - 0.3678
    52wk Range 0.3023 - 1.800
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    PPBT Stock Earnings: Purple Biotech Beats EPS for Q2 2024
    PPBT stock results show that Purple Biotech beat analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    Purple Biotech Receives Extension to Regain Compliance with the Nasdaq’s Minimum Bid Price Rule
    From Purple Biotech Ltd.
    Via GlobeNewswire

    Performance

    YTD
    -52.27%
    -52.27%
    1 Month
    +4.79%
    +4.79%
    3 Month
    -34.69%
    -34.69%
    6 Month
    -46.71%
    -46.71%
    1 Year
    -71.04%
    -71.04%

    More News

    Read More
    Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds
    From Purple Biotech Ltd.
    Via GlobeNewswire
    Why Purple Biotech (PPBT) Shares Are Trading Lower
    Via Benzinga
    Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024
    From Purple Biotech Ltd.
    Via GlobeNewswire
    Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds
    From Purple Biotech Ltd.
    Via GlobeNewswire
    Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit
    From Purple Biotech Ltd.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer
    From Purple Biotech Ltd.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    PPBT Stock Earnings: Purple Biotech Beats EPS for Q1 2024
    Via InvestorPlace
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting
    From Purple Biotech Ltd.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024
    From Purple Biotech Ltd.
    Via GlobeNewswire
    Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology
    From Purple Biotech Ltd.
    Via GlobeNewswire
    PPBT Stock Earnings: Purple Biotech Meets EPS for Q4 2023
    Via InvestorPlace
    Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024
    From Purple Biotech Ltd.
    Via GlobeNewswire
    Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial
    From Purple Biotech Ltd.
    Via GlobeNewswire
    Purple Biotech Reaches Recommended Phase 2 Dose for NT219
    From Purple Biotech Ltd.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors
    From Purple Biotech Ltd.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.